Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.39 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.34 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296284 | 0.98 | MAPT (0.46) | MAPTTDP1NPSR1LMNAL3MBTL1 | |
| SCHEMBL28380433 | 0.87 | LMNA (0.31) | MAPTTDP1NPSR1LMNAL3MBTL1 | |
| SCHEMBL27532819 | 0.77 | HTR3E (0.41) | MAPTTDP1LMNAADRB1ALOX5 | |
| SCHEMBL14889034 | 0.77 | MAPT (0.42) | MAPTTDP1NPSR1LMNAL3MBTL1 | |
| SCHEMBL27825875 | 0.77 | HRH3 (0.35) | ALDH1A1GAAMEN1KMT2AMGLL | |
| SCHEMBL13680338 | 0.76 | L3MBTL1 (0.42) | MAPTTDP1NPSR1LMNAL3MBTL1 | |
| SCHEMBL5352313 | 0.76 | MAPT (0.42) | MAPTNPSR1LMNAL3MBTL1HTT | |
| SCHEMBL21388452 | 0.75 | MAPT (0.41) | MAPTTDP1NPSR1LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL820585 | 0.73 | MAPT (0.41) | MAPTTDP1NPSR1LMNAL3MBTL1 | |
| SCHEMBL223853 | 0.70 | MAPT (0.42) | MAPTTDP1NPSR1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1075 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118169271-A | Method for detecting alpha-adrenergic receptor blocker, SSRI and 5-ARIs and application thereof | 巴中市产品质量检验检测中心 | 2024-06-11 | — | — | CN | claimed |
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| CN-103479579-A | Industrialized production of liposome combination medicine by molecular dispersion method, and quality control technology | CAI HAIDE | 2014-01-01 | — | — | CN | claimed |
| CN-103446054-A | Liposome combination drugs, industrial production process of liposome combination drug through molecular dispersion method, and quality control | CAI HAIDE | 2013-12-18 | — | — | CN | claimed |
| CN-102885798-A | Orally disintegrating tablet | CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD | 2013-01-23 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| CN-102218038-A | Formula, preparation method and application of tolazoline hydrochloride liposome combination medicine | XUEFENG DENG | 2011-10-19 | — | — | CN | claimed |
| CN-101912363-A | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine | HAIDE CAI | 2010-12-15 | — | — | CN | claimed |
| US-6514536-B2 | Topical gel; containing vasodilator | L.A.M. PHARMACEUTICAL CORPORATION | 2003-02-04 | — | — | US | claimed |
| US-20010022975-A1 | Drug preparations for treating sexual dysfunction | L.A.M. PHARMACEUTICAL CORPORATION | 2001-09-20 | — | — | US | claimed |
| EP-1112061-A1 | DRUG PREPARATIONS FOR TREATING SEXUAL DYSFUNCTION | L.A.M. Pharmaceuticals Corp. (US) | 2001-07-04 | — | — | EP | claimed |
| US-6251436-B1 | Drug preparations for treating sexual dysfunction | L.A.M. PHARMACEUTICAL CORPORATION | 2001-06-26 | — | — | US | claimed |
| WO-2000013664-A1 | DRUG PREPARATIONS FOR TREATING SEXUAL DYSFUNCTION | L.A.M. PHARMACEUTICAL CORP (US) | 2000-03-16 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5688510-A | POWDER, MACROLOLECULAR ADDITIVE | NIPPON SHINYAKU CO. LTD. (JP) | 1997-11-18 | — | — | US | claimed |
| EP-0729748-A1 | PROCESS FOR PRODUCING STABLE MEDICINAL COMPOSITION, AND PHARMACEUTICAL PREPARATION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-04 | — | — | EP | claimed |
| US-5328453-A | Method for enhancing transdermal drug delivery of electrical drug applicators | DRUG DELIVERY SYSTEMS INC. (US) | 1994-07-12 | — | — | US | claimed |
| US-4127118-A | Method of effecting and enhancing an erection | ELSA LATORRE, EXECUTRIX | 1978-11-28 | — | — | US | claimed |